Novo Nordisk A/S (Novo Nordisk A/S) COGS-to-Revenue : 0.15 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S COGS-to-Revenue?

Novo Nordisk A/S's Cost of Goods Sold for the three months ended in Dec. 2023 was $1,465 Mil. Its Revenue for the three months ended in Dec. 2023 was $9,636 Mil.

Novo Nordisk A/S's COGS to Revenue for the three months ended in Dec. 2023 was 0.15.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Novo Nordisk A/S's Gross Margin % for the three months ended in Dec. 2023 was 84.80%.

Novo Nordisk A/S COGS-to-Revenue Historical Data

The historical data trend for Novo Nordisk A/S's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S COGS-to-Revenue Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.16

0.17

0.16

0.15

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.17	0.15	0.14	0.17	0.15

Novo Nordisk A/S COGS-to-Revenue Calculation

Novo Nordisk A/S's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5232.779	/	33982.121
	=	0.15

Novo Nordisk A/S's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1465.149	/	9636.42
	=	0.15

Novo Nordisk A/S (OTCPK:NONOF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Novo Nordisk A/S's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1465.149 / 9636.42
	=	84.80 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Novo Nordisk A/S COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.